Diabetes Family Medicine Board Review
|
|
- Sybil Greene
- 6 years ago
- Views:
Transcription
1 Diabetes Family Medicine Board Review Sarah Kim, MD Associate Clinical Professor of Clinical Medicine, UCSF Division of Endocrinology, SFGH March 21, 2018
2 No disclosures
3 Diabetes Test Topics Majority Type 2 Diabetes (vs. Type 1) Medications mechanism of action, contraindications Standards of care (CVD risk reduction, etc) Treatment of complications Newest medications & recommendations unlikely to be on the test 3
4 Case #1 64 y.o. man with HTN, CAD, CHF and hyper-tg with a prior episode of pancreatitis is found to have a random plasma glucose of 205 mg/dl on labs obtained for another reason. An A1C was obtained and was 6.4%. The patient has no symptoms such as polyuria, polydipsia or polyphagia. Does he meet the criteria for the diagnosis of diabetes? 4
5 Diagnosis of Diabetes & Pre-diabetes Pre-Diabetes Criteria Diabetes Criteria* Fasting Glucose mg/dl 126 mg/dl 2 hour post 75g OGTT mg/dl 200 mg/dl Random glucose N/A 200 with symptoms of hyperglycemia HbA1c %** 6.5%** *unless unequivocally hyperglycemic, results should be confirmed with another or repeat test **in absence of anemia or hemoglobinopathy Diabetes Care, Vol 35, Supp 1, 2012
6 Case #1 continued You obtain a fasting BG which is 154 mg/dl confirming the diagnosis of diabetes mellitus for which he has a strong family history. You obtain further labs and plan to start treatment. MEDS: furosemide 40 mg BID KCl 20 meq ASA 81 mg lisinopril 40 mg metoprolol 100 mg BID LABS: A1C = 6.4%, EXAM: 100 kg; BMI 32; BP 145/95 sitting, 120/84 standing Lungs: CTA CV: S3 gallop Ext: 1+ edema, feet with no ulcerations, normal monofilament exam Lipids: TC 350;LDL NC;HDL 22;TG 505 egfr 44 6
7 Case #1 Which of the following medications would be the most appropriate initial therapy for this patient s DM2? A. metformin B. bromocriptine C. colesevalem D. pioglitazone E. glipizide F. exenatide 7
8 Case #1 Which of the following medications would be the most appropriate initial therapy for this patient s DM2? A. metformin B. bromocriptine C. colesevalem D. pioglitazone E. glipizide F. exenatide 8
9 Beta Cell Loss in Diabetes Non Diabetic T1DM T2DM
10 Sulfonylureas Mechanism: binds ATP-dependent K+ channels on surface of beta cells opening voltage gated Ca++ channels release of insulin. Lower A1C 1-2% Advantages Long history of use & cheap Disadvantages Weight gain ( 2 kg) Hypoglycemia Must be dose reduced in renal and liver Ongoing, unsettled debate on whether SU s increase CV mortality 10
11 Sulfonylureas 2 nd generation Duration Daily Dose Glipizide 6-12hr (XL version= 24 hr) mg once daily or 2 divided doses Glyburide 20-24hr mg once daily Glimepiride 24hr 2-4 mg once daily 1 st generation Duration Daily Dose Chlorpropamide 24-72hr mg once daily Tolbutamide 6-12hr mg in 2-3 divided doses Tolazamide 10-24hr mg daily U. Masharani and M. German, Ch 18 Pancreatic Hormones and Diabetes Mellitus. In: D Shoback and D Gardner (editors): Greenspan s Basic and Clinical Endocrinology, 8 th edi. McGraw Hill 2007.
12 Meglitinides Enhances insulin release like sulfonylureas Repaglinide lowers A1C 1-1.5%; Nateglinide % Advantages: Short acting (take 15 minutes prior to meals) Repaglinide undergoes little renal clearance Disadvantages qac dosing Hypoglycemia (less than sulfonylureas) More expensive than SU 12
13 Meglitinides Drug Duration of Action Daily Dose Nateglinide 1.5 hr mg qac Repaglinide 3 hr 0.5-2mg qac U. Masharani and M. German, Ch 18 Pancreatic Hormones and Diabetes Mellitus. In: D Shoback and D Gardner (editors): Greenspan s Basic and Clinical Endocrinology, 8 th edi. McGraw Hill 2007.
14 Sulfonylureas Meglitinides Biguanides
15 Biguanides (Metformin) Inhibits hepatic gluconeogenesis & increases peripheral insulin sensitivity Lowers A1C 1.5-2% Advantages: Weight loss (0-2 kg) Lowers TG, LDLc; Increases HDLc No hypoglycemia when used alone Long history of use and cheap CVD and cancer benefit? Disadvantages Majority of patients with GI side effects (titrate slowly) Impaired B12 absorption (5% or more of patients) Reputation for risk of lactic acidosis (risk=small/non-existent?) 15
16 Metformin Biguanide Duration Daily Dosing Metformin 7-12 hr mg in 2-3 divided doses XR version 24 hrs mg nightly U. Masharani and M. German, Ch 18 Pancreatic Hormones and Diabetes Mellitus. In: D Shoback and D Gardner (editors): Greenspan s Basic and Clinical Endocrinology, 8 th edi. McGraw Hill
17 Contraindications: Renal insufficiency Metformin Updated recommendations based on egfr End stage liver disease (ok in mild-mod cirrhosis) Excessive alcohol use- theoretical Iodinated contrast Discontinue within 48 hrs of exposure Elderly ( 80 yo unless normal renal function)-theoretical Severe or acute CVD- particularly unstable CHF or AMItheoretical
18 TZDs Sulfonylureas Meglitinides Biguanides
19 Thiazolidinediones (TZD) Activate PPAR-γ, improve insulin sensitivity by altering gene transcription (takes 8-12 weeks for max effect) Lower A1C % CVD risk decreased with pioglitazone Advantages: Improves decreases TG, increases in HDL (pioglitazone) No hypoglycemia when used alone Rosiglitazone has reputation for being associated with MI even though FDA cleared in
20 TZDs Drug Duration Dosing Pioglitazone 24 hr mg qday Rosiglitazone 24 hr 4-8 mg qday or BID U. Masharani and M. German, Ch 18 Pancreatic Hormones and Diabetes Mellitus. In: D Shoback and D Gardner (editors): Greenspan s Basic and Clinical Endocrinology, 8 th edi. McGraw Hill 2007.
21 TZDs Adverse Event Frequency Increased Risk vs Placebo Edema 5% 2 fold Congestive Heart Failure 5% 2-7 fold Weight Gain 60% kg Fractures 2-5% 2 fold Bladder Cancer 0.3% 20%
22 TZDs Sulfonylureas Meglitinides Biguanides SGLT2 inhibitors
23 Sodium Glucose Co-Transporter 2 Inhibitors Sodium-glucose cotransporter 2 (SGLT2) plays a major role in renal glucose reabsorption in proximal tubule Renal glucose reabsorption is increased in type 2 diabetes Selective inhibition of SGLT2 increases urinary glucose excretion, reducing blood glucose J Intern Med. 2007;261:32-43.
24 Renal Handling of Glucose (180 L/day) (900 mg/l)=162 g/day Glucose SGLT2 S1 90% S3 SGLT1 10% J Intern Med. 2007;261: Endocr Pract. 2008;14: No Glucose
25 Dapagliflozin: Glucosuric and Metabolic Effects Glucosuria FPG PPG g/day mg/dl mg/dl Body weight kg ( 2.5%-3.4%) Urine volume ml/day List JF, et al. Diabetes Care. 2009;32:
26 SGLT2 Inhibitors Lowers A1C about 0.6-1% at max dose No hypoglycemia when used alone or with metformin Advantages Weight loss kg Decrease in SBP 5 mmhg CV mortality benefit- FDA approved for CV indication in T2DM Reduces albuminuria Disadvantages Increased mycotic genital infections in men (4%) and women (10%) UTIs (5%) Bladder cancer concern Polyuria, presyncope/sycope, fractures Increases Cr, decreases egfr (contraindicated in lower GFR), hyperkalemia $$$
27 Empagliflozin Trial: CV OUTCOMES & DEATH FROM ANY CAUSE Zinman B et al. N Engl J Med 2015;373:
28 SGLT2 Inhibitors Duration Dose Canagliflozin* 24 hrs mg daily Dapagliflozin* 24 hrs 5-10mg daily Empagliflozin* 24 hrs mg daily **Empagliflozin is also FDA approved indication to reduce CV event in type 2 diabetes * Renal dosing/contraindicated in renal failure
29 Case #1 continued 64 yom with HTN, CAD, CHF and hypertg with a prior episode of pancreatitis is found to have a random plasma glucose of 205 mg/dl on labs obtained for another reason. The patient has no symptoms such as polyuria, polydipsia or polyphagia. MEDS: furosemide 40 mg BID KCl 20 meq ASA 81 mg lisinopril 40 mg metoprolol 100 mg BID LABS: A1C = 8.8%, EXAM: 100 kg; BMI 32; BP145/94 Lungs: CTA CV: S3 gallop Ext: 1+ edema, feet with no ulcerations, normal monofilament exam Lipids: TC 350;LDL NC;HDL 22;TG 505 egfr 44 29
30 Case #1 Which choice below would be the most appropriate initial therapy for this patient s DM2? A. metformin B. glyburide C. canagliflozin D. pioglitazone E. glipizide F. exenatide 30
31 Case #2 54 yow with DM2 diagnosed 7 years ago presents to you for f/u complaining of increasing hypoglycemia and several URIs. At your last visit you added sitigliptin (Januvia) to her medications for an A1C of 7.6% and persistent SMBG values in the 200s. DM MEDS: metformin 1 gm BID glyburide 10 mg daily sitagliptin 100 mg daily LABS: A1C = 7.0%, egfr is 45 ml/min Which of the following statements is true? The addition of sitigliptin: A. Did not contribute to hypoglycemia B. Should have been dose adjusted for renal insufficiency C. Was not related to the increased number of URIs D. Typically results in a 1-2 kg weight loss 31
32 Case #2 54 yow with DM2 diagnosed 7 years ago presents to you for f/u complaining of increasing hypoglycemia and several URIs. At your last visit you added sitigliptin (Januvia) to her medications for an A1C of 7.6% and persistent SMBG values in the 200s. DM MEDS: metformin 1 gm BID glyburide 10 mg daily sitagliptin 100 mg daily LABS: A1C = 7.0%, egfr is 45 ml/min Which of the following statements is true? The addition of sitigliptin: A. Did not contribute to hypoglycemia B. Should have been dose adjusted for renal insufficiency C. Was not related to the increased number of URIs D. Typically results in a 2-3 kg weight loss 32
33 GLP-1 Agonists DPP-4 Inhibitors α-glucosidase Inhibitors Bile Acid Sequestrants Sulfonylureas Meglitinides TZDs Biguanides SGLT2 inhibitors
34 The Incretin Effect 34
35 What Incretins Do Incretins: -Enhance insulin secretion -Suppress glucagon secetion -Slow gastric emptying -Promote satiety J Fam Med. October 2009 Vol. 58, No. 10
36 GLP-1 Analogs Resistant to degradation by DPP4 and have a long halflife Lower HbA1C % Advantages: Weight loss (2-3 kg); less hypoglycemia CV mortality benefit (liraglutide) Disadvantages: Injectable GI Side Effects (nausea, vomiting) Pancreatitis, medullary thyroid cancer? 36
37 Reduction in CV outcomes with Liraglutide CV Death HR 0.78( ), p=0.007 Marso SP et al. N Engl J Med 2016;375: Marso SP et al. N Engl J Med 2016;375:
38 DPP-4 Inhibitors Increases GLP-1 and GIP levels Lowers A1C % Use in conjunction with other oral hypoglycemic agents in DM2 or as monotherapy Advantages: Oral, weight neutral Disadvantages: $$ Increased incidence of URI, nasophyrngitis (mechanism?) 38
39 Incretin-based therapies GLP-1 Agonists Duration Daily Dose Exenatide* 6hr (ER version 1 wk) 5-10mcg BID subcut. before meals (ER version 2 mg weekly) Liraglutide** hr mg subcut. daily Dulaglutide 1 wk mg weekly ** Liraglutide also has FDA approved indication to lower CV events in T2DM DPP-4 Inhibitors Duration Daily Dose Sitagliptin* 24 hr mg Daily Saxagliptin* 24 hr mg Daily Linagliptin 24 hr 5 mg Daily Alogliptin* 24 hr 25 mg Daily *renal dosing required U. Masharani and M. German, Ch 18 Pancreatic Hormones and Diabetes Mellitus. In: D Shoback and D Gardner (editors): Greenspan s Basic and Clinical Endocrinology, 8 th edi. McGraw Hill 2007.
40 α-glucosidase Inhibitors Reversible competitive inhibition of a-glucosidase difficulty breaking down disaccharides and complex carbs Lowers A1C % by improving postprandial glucose Advantages: No hypoglycemia when used alone; weight neutral Disadvantages: GI SE, flatulance; TID dosing Caution with hypoglycemia, sucrose is ineffective 40
41 α-glucosidase Inhibitors Duration Daily Dose Acarbose 4 hr mg in 3 divided doses with meals Miglitol 4 hr mg in 3 divided doses with meals U. Masharani and M. German, Ch 18 Pancreatic Hormones and Diabetes Mellitus. In: D Shoback and D Gardner (editors): Greenspan s Basic and Clinical Endocrinology, 8 th edi. McGraw Hill 2007.
42 Bile Acid Sequestrant Colasevelam Approved for years for cholesterol lowering Lowers HbA1C 0.4% (mechanism largely unknown) Advantages: Lowers LDLc Disadvantages: GI side effects (bloating, cramping, constipation) Increases triglycerides (avoid if TG >500) Impairs absorption of fat soluble vitamins, digoxin, warfarin, thiazides, beta blockers, thyroxine, phenobarbital 42
43 HbA1c Lowering by Non-Insulin Drug Medications AIC lowering when used as monotherapy Metformin 1.5-2% Sulfonylureas 1-2% Thiazolidinediones % GLP-1 Agonists % Meglitinides % SGLT2 inhibitors 0.6-1% Lifestyle % DPP4 inhibitors % α-glucosidase inhibitors % Bile acid sequestrant 0.4% Bromocriptine < 0.2%
44 Case #3 You are asked to see a 72 year old man with CHF (NYHA class III) with previously well controlled DM2, but now a HbA1c of 9.1%. He is on glyburide and metformin at max doses. What is the most appropriate change to his regimen? A. Add pioglitazone B. Add basal insulin (NPH or glargine) C. Add acarbose D. Add saxagliptin
45 Case #3 You are asked to see a 72 year old man with CHF (NYHA class III) with previously well controlled DM2, but now a HbA1c of 9.1%. He is on glyburide and metformin at max doses. What is the most appropriate change to his regimen? A. Add pioglitazone B. Add basal insulin (NPH or glargine) C. Add acarbose D. Add saxagliptin
46 Well-Validated Core Therapy for DM2 At Diagnosis: Lifestyle and Metformin Add Basal Insulin Add Sulfonylurea Nathan DM et al. Diab Care 2009;32:
47 Basal Insulin NPH Glargine Detemir Pros 1. Variable dosing possible at different times of day 2. Can be mixed with other insulin types Cons 1. 2 injections/day 2. Peaks 6-8 hrs after injection 1. Usually only one injection needed 2. Generally peakless 1. Cannot be mixed with other insulin types 1. Variable dosing possible at different times of day 2. Mild peak 1. 2 injections/day 2. Cannot be mixed with other insulin types HbA1C 7% Total Dose Cost ( No difference between NPH, Glargine, and Detemir No difference between NPH, Glargine, and Detemir $ $$ $$ Cochrane Database of Systematic Reviews (2009) Issue 2. Art No CD006613
48 Basal Insulin Degludec Basaglar U300 Glargine Pros 1. Can inject within an 8 hr window daily 2. Peakless 3. Comes in a premix pen Cons 1. Expensive 2. Pen only 1. generic lantus 2. Slightly cheaper than Lantus 1. Expensive 2. Pen only 1. Smaller volume injection 2. Generally peakless 1. Expensive 2. Pen only HbA1C 7% Total Dose Cost ( No differences U300 may need slightly higher dose $$$ $$ $$$
49 Hypoglycemia with basal insulin Hypoglycemia Nocturnal Hypoglycemia NPH vs Glargine or Detemir ~17% more with NPH ~35% more with NPH * Driven by studies with aggressive titration strategies Cochrane Database of Systematic Reviews (2009) Issue 2. Art No CD006613
50 Well-Validated Core Therapy for DM2 At Diagnosis: Lifestyle and Metformin Add Basal Insulin Add Sulfonylurea Nathan DM et al. Diab Care 2009;32:
51 Less Well-Validated Buffet for DM2 ADA Standards of Medical Care in Diabetes 2017
52 Case #4 66 yom with DM2 for 5 years started on insulin 2 years ago but still can t get A1C below 8.0%. Patient reports no symptomatic lows. DM Meds: Metformin 1 gm BID NPH 20 units am, 10 units at bedtime Regular 5 units before each meal Time What would be the best next step for improving A1C? A. Change NPH to glargine 30 units B. Increase morning NPH dose to 25 units C. Increase mealtime R insulin dose to 8 units before each meal D. Increase dinnertime R insulin to 8 units E. Change R to aspart insulin Glucose Range Fasting Pre-Lunch Pre-Dinner Bedtime
53 Case #4 66 yom with DM2 for 5 years started on insulin 2 years ago but still can t get A1C below 8.5%. Patient reports no symptomatic lows. DM Meds: Metformin 1 gm BID NPH 20 units am, 10 units at bedtime Regular 5 units before each meal Time What would be the best next step for improving A1C? A. Change NPH to glargine 30 units B. Increase morning NPH dose to 25 units C. Increase mealtime R insulin dose to 8 units before each meal D. Increase dinnertime R insulin to 8 units E. Change R to aspart insulin Glucose Range Fasting Pre-Lunch Pre-Dinner Bedtime
54 Glycemic Goals in Diabetes For Most Adults: Fasting Glucose mg/dl Peak Post-Prandial Glucose <180 mg/dl HbA1c 7.0% Time Glucose Range Fasting Pre-Lunch Pre-Dinner Glycemic goals differ in: pregnancy (lower goals) Bedtime children, limited life expectancy, hypoglycemia unawareness, significant cardiovascular disease (higher goals) Diabetes Care (2011) 34: s11-s61
55 Normal Plasma Insulin Profile Insulin µu/ml Basal insulin o o o Near-constant levels Important during night/between meals 50% or more of daily needs B L D Mealtime insulin o o o Limits hyperglycemia after meals Rise and peak post meal 10% to 20% of daily needs at each meal B=breakfast; L=lunch; D=dinner Time of day Polonsky KS et al. N Engl J Med. 1988;318:
56 Types of Insulin Basal Insulin Peak Duration NPH 4-8 hrs 10-20hr Glargine None 24 hr Detemir Small 17 hr Degludec none 36 hr Bolus Insulin Peak Duration Regular 2 hr 6 hr Aspart 1 hr 3-4 hr Lispro 1 hr 3-4 hr Glulisine 1 hr 3-4 hr Combination Insulin Composition 70%/30% 70% NPH 30% Regular or Aspart 75%/25% 75% NPH 25% Lispro 50%/50% 50%NPH 50% Lispro 56
57 Basal-Bolus Insulin Treatment µu/ml NPH B L D NPH at bedtime Normal pattern Time of day
58 Basal-Bolus Insulin Treatment µu/ml B L D Glargine Normal pattern Time of day
59 Basal-Bolus Insulin Treatment µu/ml Meal time insulin B L D Glargine Normal pattern Time of day
60 Case #5 A 64 year old woman with DM presents with worsening glycemic control. Fasting glucose values are constantly above 200. She doesnt check BS at other times of the day. Medicines include metformin 1 g BID and glipizide 10 mg BID. A1C 9.1%. Of the options listed below, which is the most appropriate therapy for this patient? A. Start morning NPH or glargine and discontinue all oral agents B. Start morning NPH or glargine, maintain sulfonylurea and discontinue metformin C. Start bedtime NPH or insulin glargine, discontinue metformin and continue sulfonylurea. D. Start bedtime NPH or glargine, maintain oral agents
61 Case #5 A 64 year old woman with DM presents with worsening glycemic control. Fasting glucose values are constantly above 200. She doesn t check BS at other times of the day. Medicines include metformin 1 g BID and glipizide 10 mg BID. A1C 9.1%. Of the options listed below, which is the most appropriate therapy for this patient? A. Start morning NPH or glargine and discontinue all oral agents B. Start morning NPH or glargine, maintain sulfonylurea and discontinue metformin C. Start bedtime NPH or insulin glargine, discontinue metformin and continue sulfonylurea. D. Start bedtime NPH or glargine, maintain oral agents
62 Case #6 67 yom has had DM2 for 2 yrs treated with metformin and glipizide. He also has schizophrenia and started olanzapine 3 months ago. Since then, he gained 20 lbs and his HbA1c increased from %. What should you do to help improve his diabetic control? a. Have a home health nurse assist him with medication compliance b. Add pioglitazone 30mg daily to increase insulin sensitivity c. Contact the treating psychiatrist about possibly changing his antipsychotic d. Add exenatide 10 mcg BID to assist with weight loss e. Switch from glipizide to glyburide
63 Case #6 67 yom has had DM2 for 2 yrs treated with metformin and glipizide. He also has schizophrenia and started olanzapine 3 months ago. Since then, he gained 20 lbs and his HbA1c increased from %. What should you do to help improve his diabetic control? a. Have a home health nurse assist him with medication compliance b. Add pioglitazone 30mg daily to increase insulin sensitivity c. Contact the treating psychiatrist about possibly changing his antipsychotic medication d. Add exenatide 10 mcg BID to assist with weight loss e. Switch from glipizide to glyburide
64 Metabolic side effects of second generation antipsychotics Most weight gain Less weight gain No weight gain Olanzapine Quetiapine Aripiprazole Clozapine Risperidone Ziprasidone Iloperidone Lurasidone Paliperidone
65 Case #7 49 yow with DM2 is seeing you for follow up. Her A1c is 7.3% on metformin, glyburide and significant lifestyle modifications that she has made over the years. She has HTN and albuminuria for which she takes lisinopril. Her recent lipid panel reveals a Tchol of 200, LDL of 90, HDL of 39, TG 190. How do you respond to her lipid panel? A. Begin colasevelam 1875 mg BID B. Begin pioglitazone 30mg daily C. Begin atorvastatin 40 mg daily D. Assure her that she has reached the LDL goal for diabetes without medications E. Ask her about a family history of early MI
66 Case #7 49 yow with DM2 is seeing you for follow up. Her A1c is 7.3% on metformin, glyburide and significant lifestyle modifications that she has made over the years. She has HTN and albuminuria for which she takes lisinopril. Her recent lipid panel reveals a Tchol of 200, LDL of 90, HDL of 39, TG 190 How do you respond to her lipid panel? A. Begin colasevelam 1875 mg BID B. Begin pioglitazone 30mg daily C. Begin atorvastatin 40 mg daily D. Assure her that she has reached the LDL goal for diabetes without medications E. Ask her about a family history of early MI
67 Statin recommendations for DM
68 Case #8 50 yom with DM2 x 8 yrs, HTN, and dyslipidemia has an A1c of 8.5%. He has a family history of early MI. Lowering HbA1c to 7% will NOT reduce his risk of developing: A. Retinopathy B. Nephropahty C. Myocardial infarction D. Neuropathy
69 Case #8 50 yom with DM2 x 8 yrs, HTN, and dyslipidemia has an A1c of 8.5%. He has a family history of early MI. Lowering HbA1c to 7% will NOT reduce his risk of developing: A. Retinopathy B. Nephropahty C. Myocardial infarction D. Neuropathy
70 Tight control trials 1977 UKPDS (DM2) * 1983 DCCT (DM1) * 2000 VADT (DM2) 2001 ADVANCE (DM2) * 2001 ACCORD (DM2) *showed that tight control lowers microvascular complications
71 My go-to diabetes resource: Search: ADA Standards of Medical Care in Diabetes updated every January 71
No disclosures. Diabetes Test Topics. Case #1. Diabetes Family Medicine Board Review: Improving Clinical Care Across the Lifespan
Diabetes Family Medicine Board Review: Improving Clinical Care Across the Lifespan No disclosures Sarah Kim, MD Assistant Clinical Professor of Clinical Medicine, UCSF Division of Endocrinology, SFGH March
More informationDiabetes Family Medicine Board Review
Diabetes Family Medicine Board Review Sarah Kim, MD Assistant Clinical Professor of Clinical Medicine, UCSF Division of Endocrinology, SFGH March 10, 2016 No disclosures Diabetes Test Topics Majority Type
More informationType 2 Diabetes: Where Do We Start with Treatment? DIABETES EDUCATION. Diabetes Mellitus: Complications and Co-Morbid Conditions
Diabetes Mellitus: Complications and Co-Morbid Conditions ADA Guidelines for Glycemic Control: 2016 Retinopathy Between 2005-2008, 28.5% of patients with diabetes 40 years and older diagnosed with diabetic
More informationAntihyperglycemic Agents in Diabetes. Jamie Messenger, PharmD, CPP Department of Family Medicine East Carolina University August 18, 2014
Antihyperglycemic Agents in Diabetes Jamie Messenger, PharmD, CPP Department of Family Medicine East Carolina University August 18, 2014 Objectives Review 2014 ADA Standards of Medical Care in DM as they
More informationWhat s New in Diabetes Treatment. Disclosures
What s New in Diabetes Treatment Shiri Levy M.D. Henry Ford Hospital Senior Staff Physician Service Chief, West Bloomfield Hospital Endocrinology, Metabolism, Bone and Mineral Disorders Disclosures None
More informationJoslin Diabetes Center Joslin Diabetes Forum 2013: The Impact of Comorbidities on Glucose Control Scenario 2: Reduced Renal Function
Scenario 2: Reduced Renal Function 62 y.o. white man with type 2 diabetes for 18 years Hypertension and hypercholesterolemia Known proliferative retinopathy Current medications: Metformin 1000 mg bid Glyburide
More informationWayne Gravois, MD August 6, 2017
Wayne Gravois, MD August 6, 2017 Americans with Diabetes (Millions) 40 30 Source: National Diabetes Statistics Report, 2011, 2017 Millions 20 10 0 1980 2009 2015 2007 - $174 Billion 2015 - $245 Billion
More informationNEW DIABETES CARE MEDICATIONS
NEW DIABETES CARE MEDICATIONS James Bonucchi DO, ECNU, FACE Adult Medicine and Endocrinology Specialists Disclosures Speakers bureau Sanofi AZ BI Diabetes Diabetes cost ADA 2017 data Ever increasing disorder.
More information7/8/2016. Sol Jacobs MD, FACE Division of Endocrinology Emory University School of Medicine
Sol Jacobs MD, FACE Division of Endocrinology Emory University School of Medicine Participation in investigator initiated clinical research supported by: Merck Boehringer Ingelheim Novo Nordisk Astra Zeneca
More informationObjectives. Recognize all available medical treatment options for diabetes. Individualize treatment and glycemic target based on patient factors
No disclosure Objectives Recognize all available medical treatment options for diabetes Individualize treatment and glycemic target based on patient factors Should be able to switch to more affordable
More informationManagement of Diabetes
Management of Diabetes Mellitus: Which Drugs for Which Patients? Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine baron@medicine.ucsf.edu Disclosure No relevant financial relationships
More informationA Practical Approach to the Use of Diabetes Medications
A Practical Approach to the Use of Diabetes Medications Juan Pablo Frias, M.D., FACE President, National Research Institute, Los Angles, CA Clinical Faculty, University of California, San Diego, CA OUTLINE
More informationType 2 Diabetes Mellitus 2011
2011 Michael T. McDermott MD Director, Endocrinology and Diabetes Practice University of Colorado Hospital Michael.mcdermott@ucdenver.edu Diabetes Mellitus Diagnosis 2011 Diabetes Mellitus Fasting Glucose
More informationWhat s New in Diabetes Medications. Jena Torpin, PharmD
What s New in Diabetes Medications Jena Torpin, PharmD 1 Objectives Discuss new medications in the management of diabetes Understand the mechanism of the medications discussed Understand the side effects
More informationGlucose Control drug treatments
Glucose Control drug treatments It should be noted that glitazones are under suspicion of precipitating acute cardiac events and current recommendations contraindicate the use of glitazones in patients
More informationManagement of Diabetes Mellitus: A Primary Care Perspective. Screening for Diabetes Advantages of HbA1c as a Diagnostic Test
Management of Diabetes Mellitus: A Primary Care Perspective Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest Screening
More informationPharmacology Updates. Quang T Nguyen, FACP, FACE, FTOS 11/18/17
Pharmacology Updates Quang T Nguyen, FACP, FACE, FTOS 11/18/17 14 Classes of Drugs Available for the Treatment of Type 2 DM in the USA ### Class A1c Reduction Hypoglycemia Weight Change Dosing (times/day)
More informationMultiple Small Feedings of the Mind: Diabetes. Sonja K Fredrickson, MD, BC-ADM March 7, 2014
Multiple Small Feedings of the Mind: Diabetes Sonja K Fredrickson, MD, BC-ADM March 7, 2014 Question 1: Setting A1c Goals Describe the evidence based approach to determining the target HgbA1c in different
More informationManagement of Diabetes Mellitus: A Primary Care Perspective
Management of Diabetes Mellitus: A Primary Care Perspective Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest Screening
More informationWhat s New on the Horizon: Diabetes Medication Update
What s New on the Horizon: Diabetes Medication Update Outline of Talk Newly released and upcoming medications: the incretins, DPP-IV inhibitors, and what s coming Revised ADA/EASD and AACE guidelines:
More informationCURRENT ISSUES IN DIABETES MANAGEMENT. Screening for Diabetes Advantages of HbA1c as a Diagnostic Test. Diagnosis of Diabetes 2013
CURRENT ISSUES IN DIABETES MANAGEMENT Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest Screening for Diabetes 2013 BMI
More informationPharmacology Update for the Adult Patient - Newer Oral Medications for Diabetes
Pharmacology Update for the Adult Patient - Newer Oral Medications for Diabetes Brooke Hudspeth, PharmD, CDE, MLDE Director of Diabetes Prevention, Kroger Pharmacy Adjunct Assistant Professor, University
More informationDM Fundamentals Class 4 Meds for Type 2
DM Fundamentals Class 4 Meds for Type 2 Beverly Thomassian, RN, MPH, BC ADM, CDE President, Diabetes Education Services Copyright 1999 2015, Diabetes Education Services, All Rights Reserved. Diabetes Meds
More informationDiabetes Oral Agents Pharmacology. University of Hawai i Hilo Pre-Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D
Diabetes Oral Agents Pharmacology University of Hawai i Hilo Pre-Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D 1 Learning Objectives Understand the role of the utilization of free
More informationIndividualizing Care for Patients with Type 2 Diabetes
Individualizing Care for Patients with Type 2 Diabetes Disclosures Speaker: AstraZeneca, Novo Nordisk, BI/Lilly, Valeritas, Takeda Advisor: Tandem Diabetes, Sanofi Objectives Develop individualized approaches
More informationNewer Drugs in the Management of Type 2 Diabetes Mellitus
Newer Drugs in the Management of Type 2 Diabetes Mellitus Dr. C. Dinesh M. Naidu Professor of Pharmacology, Kamineni Institute of Medical Sciences, Narketpally. 1 Presentation Outline Introduction Pathogenesis
More informationOral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy
Oral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy Jeffrey Boord, MD, MPH Advances in Cardiovascular Medicine Kingston, Jamaica December 7, 2012 VanderbiltHeart.com Outline
More informationOral Medication for the Management of Diabetes Mechanism of. Duration of Daily Dosing Action
Glyburide (Micronase, Diabeta, Glynase) Glipizide (Glucotrol) Glipizide XL (Glucotrol XL) Glimepiride (Amaryl) Prandin (Repaglinide) Starlix (Nateglinide) 1.25, 2.5, 5mg tabs, Dosing: 2.5-20 mg 12- (Glynase:
More informationWhat s New on the Horizon: Diabetes Medication Update. Michael Shannon, MD Providence Endocrinology, Olympia WA
What s New on the Horizon: Diabetes Medication Update Michael Shannon, MD Providence Endocrinology, Olympia WA 1 Outline of Talk Newly released and upcoming medications: the incretins, DPP-IV inhibitors,
More informationDM Fundamentals Class 4 Meds for Type 2
DM Fundamentals Class 4 Meds for Type 2 Beverly Thomassian, RN, MPH, BC ADM, CDE President, Diabetes Education Services Copyright 1999 2015, Diabetes Education Services, All Rights Reserved. Diabetes Meds
More informationComprehensive Diabetes Treatment
Comprehensive Diabetes Treatment Joshua L. Cohen, M.D., F.A.C.P. Professor of Medicine Interim Director, Division of Endocrinology & Metabolism The George Washington University School of Medicine Diabetes
More informationOral and Injectable Non-insulin Antihyperglycemic Agents
Appendix 5: Diabetes Education and Medical Management in Adults with Diabetes Oral and Injectable Non-insulin s This directive will be implemented by RPhs, RNs or RDs who have been deemed authorized implementers.
More informationSociety for Ambulatory Anesthesia Consensus Statement on Perioperative Blood Glucose Management in Diabetic Patients Undergoing Ambulatory Surgery
Society for Ambulatory Anesthesia Consensus Statement on Perioperative Blood Glucose Management in Diabetic Patients Undergoing Ambulatory Surgery Girish P. Joshi, MB BS, MD, FFARCSI Anesthesia & Analgesia
More information9/12/2014. Main Pathophysiological Defect in T1DM. Main Pathophysiological Defects in T2DM. Personalizing Diabetes Care: The Alphabet Soup of Options
9/12/2014 Baptist Health South Florida 13th Annual Primary Focus Symposium June 28, 2014 Silvio Inzucchi MD Section of Endocrinology Yale University School of Medicine Half-Century of HTN & T2DM Medications
More informationDiabetes Treatment Update
Diabetes Treatment Update Timothy C. Evans, MD PhD FACP University of Washington Department of Medicine Disclosure: Dr. Evans has no significant financial interest in any of the products or manufacturers
More informationDiabetes Mellitus: Implications of New Clinical Trials and New Medications
Diabetes Mellitus: Implications of New Clinical Trials and New Medications Estimates of Diagnosed Diabetes in Adults, 2005 Alka M. Kanaya, MD Asst. Professor of Medicine UCSF, Primary Care CME October
More informationCardiovascular Benefits of Two Classes of Antihyperglycemic Medications
Cardiovascular Benefits of Two Classes of Antihyperglycemic Medications Nathan Woolever, Pharm.D., Resident Pharmacist Pharmacy Grand Rounds November 6 th, 2018 Franciscan Healthcare La Crosse, WI 2017
More informationYOU HAVE DIABETES. Angie O Connor Community Diabetes Nurse Specialist 25th September 2013
YOU HAVE DIABETES Angie O Connor Community Diabetes Nurse Specialist 25th September 2013 Predicated 2015 figures are already met 1 in 20 have diabetes:1in8 over 60years old Definite Diagnosis is key Early
More informationPreventing Heart Attacks and Strokes Every Day (PHASE) RCHC Medication Titration Algorithm
Preventing Heart Attacks and Strokes Every Day (PHASE) RCHC Medication Algorithm Updated 9/13/2017 PHASE Populations DM: type 2 ASCVD: hx heart attack/cad, CVA, TIA, AAA, Sx PAD Lifestyle Modifications
More informationType 2 Diabetes Mellitus Insulin Therapy 2012
Type 2 Diabetes Mellitus Therapy 2012 Michael T. McDermott MD Director, Endocrinology and Diabetes Practice University of Colorado Hospital Michael.mcdermott@ucdenver.edu Preparations Onset Peak Duration
More informationTable 1. Antihyperglycemic agents for use in type 2 diabetes
Table 1. Antihyperglycemic agents for use in type 2 diabetes DRUG IN ALPHA-GLUCOSIDASE INHIBITOR: inhibits pancreatic alpha-amyle and intestinal alpha-glucoside Acarbose (Glucobay) 0.6% Negligible Not
More information9/29/ Disclosure. Learning Objectives. Diabetes Update: Guidelines, Treatment Options & Trends
+ Diabetes Update: Guidelines, Treatment Options & Trends Melissa Max, PharmD, BC-ADM, CDE Assistant Professor of Pharmacy Practice Harding University College of Pharmacy + Disclosure Conflicts Of Interest
More informationDiabetes Mellitus II CPG
1 Diabetes Mellitus II CPG Candidates for Screening Integrated Complex Care Patients: Check Yearly Prediabetes: Check Yearly No Diabetes Mellitus (DM) Risk Factors: Check at Age 45, Repeat Every 3 Years
More informationDept of Diabetes Main Desk
Dept of Diabetes Main Desk 01202 448060 Glucose management in Type 2 Diabetes in Adults The natural history of type 2 diabetes is for HbA1c to deteriorate with time. A stepwise approach to treatment is
More informationVipul Lakhani, MD Oregon Medical Group Endocrinology
Vipul Lakhani, MD Oregon Medical Group Endocrinology Disclosures None Objectives Be able to diagnose diabetes and assess control Be able to identify appropriate classes of medications for diabetes treatment
More informationDiabetes Mellitus in Older Adults. Presenter Disclosure Information
Diabetes Mellitus in Older Adults Medha Munshi, M.D. Joslin Diabetes Center Beth Israel Deaconess Medical Center Harvard Medical School Presenter Disclosure Information Medha Munshi Research grant from
More informationAdvanced Practice Education Associates. Endocrine
Advanced Practice Education Associates Endocrine Overview Diabetes Thyroid Disease 162 Copyright 2016 Advanced Practice Education Associates DIABETES MELLITUS What is the BMI cut point for screening adults
More informationClinical Cases in Diabetes Management. Joseph Cook D.O.
Clinical Cases in Diabetes Management Joseph Cook D.O. Objectives State the prevalence of Diabetes Mellitus in Ohio State the percentage of diabetic patients in the U.S. treated by Primary Care Physicians
More information4/9/2018 HOW TO REGULATE DIABETES MEDICATIONS. By Sarah Froemsdorf MSN, RNC, CDE, FNP DISCLOSURES NONE. Diagnosis
HOW TO REGULATE DIABETES MEDICATIONS By Sarah Froemsdorf MSN, RNC, CDE, FNP DISCLOSURES NONE Diagnosis 1 NORMAL BODY The normal pancreas releases one unit of insulin every hour all day. The normal pancreas
More informationCURRENT CONTROVERSIES IN DIABETES CARE
CURRENT CONTROVERSIES IN DIABETES CARE Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest Diabetes Mellitus: U.S. Impact
More informationI. General Considerations
1 2 3 I. General Considerations A. Type I ( Juvenile Onset or IDDM) IDDM results from autoimmune destruction of beta cells inability to secrete insulin --> ketone formation --> DKA 4 Diabetic Ketoacidosis
More informationManagement of Type 2 Diabetes Mellitus. Heather Corn, MD, MS Endocrinology, Diabetes, and Metabolism
Management of Type 2 Diabetes Mellitus Heather Corn, MD, MS Endocrinology, Diabetes, and Metabolism Disclosures Working for Intermountain Healthcare Some of the views represented are the opinion of ABIM-certified
More informationDIABETES. overview of pharmacologic agents used in the management of. Overview 4/3/2014 OBJECTIVES. Injectable Agents
overview of pharmacologic agents used in the management of DIABETES Kyle Roberts, Pharm.D. PGY-1 Pharmacy Resident Saint Alphonsus RMC 1. List the different classes of diabetes medications, including the
More informationKeep Calm and Focus on the Evidence for the Management of Diabetes. Diabetes Update 2018
Keep Calm and Focus on the Evidence for the Management of Diabetes Diabetes Update 2018 Nicole C.Pezzino, PharmD, BCACP, CDE Assistant Professor, Wilkes University Pharmacist, Weis Markets Nicole.pezzino@wilkes.edu
More informationNew Therapies for Diabetes Management: Hope or Headache?
New Therapies for Diabetes Management: Hope or Headache? Elizabeth Stephens, MD, FACP PMG- Endocrinology Elizabeth.Stephens@providence.org November 2018 Disclosures None 1 Objectives Discussion of 3 rd
More informationAbbreviations DPP-IV dipeptidyl peptidase IV DREAM Diabetes REduction Assessment with ramipril and rosiglitazone
Index Abbreviations DPP-IV dipeptidyl peptidase IV DREAM Diabetes REduction Assessment with ramipril and rosiglitazone Medication GAD glutamic acid decarboxylase GLP-1 glucagon-like peptide 1 NPH neutral
More informationInitiating Injectable Therapy in Type 2 Diabetes
Initiating Injectable Therapy in Type 2 Diabetes David Doriguzzi, PA C Learning Objectives To understand current Diabetes treatment guidelines To understand how injectable medications fit into current
More informationJonathan Stoehr, MD PhD Endocrinology, Diabetes, Metabolism and Nutrition Virginia Mason Medical Center Seattle, WA 2012 Virginia Mason Medical
Jonathan Stoehr, MD PhD Endocrinology, Diabetes, Metabolism and Nutrition Virginia Mason Medical Center Seattle, WA There is no conflict of interest that could be perceived as prejudicing the impartiality
More informationLearning and Earning with Gateway Professional Education CME/CEU Webinar Series. Diabetes Update July 6, :00pm 1:00pm
Learning and Earning with Gateway Professional Education CME/CEU Webinar Series Diabetes Update July 6, 2017 12:00pm 1:00pm Jennifer Pennock Holst, MD Endocrinology, Diabetes & Metabolism AHN Center for
More informationTREATMENT OF DIABETES AFTER METFORMIN GREGG GERETY, MD ALBANY MEDICAL COLLEGE, DIVISION OF COMMUNITY ENDOCRINOLOGY JULY 14, 2017
TREATMENT OF DIABETES AFTER METFORMIN GREGG GERETY, MD ALBANY MEDICAL COLLEGE, DIVISION OF COMMUNITY ENDOCRINOLOGY JULY 14, 2017 Outline Review treatment algorithms from ADA/ EASD & ACE/AACE. Review positive
More informationRPCC Pharmacy Forum. The Type 2 Diabetes Issue. Type 2 Diabetes: The Basics
Nov/Dec 2015 Issue 11 RPCC Pharmacy Forum Special Interest Articles: Diabetes Medication Chart Insulin Chart Afreeza Did you know? Exanatide, marketed as Byetta, is the synthetic form of exendin-4, which
More informationMae Sheikh-Ali, M.D. Assistant Professor of Medicine Division of Endocrinology University of Florida College of Medicine- Jacksonville
Mae Sheikh-Ali, M.D. Assistant Professor of Medicine Division of Endocrinology University of Florida College of Medicine- Jacksonville Pathogenesis of Diabetes Mellitus (DM) Criteria for the diagnosis
More informationPharmacologic Agents for Treatment of Type 2 Diabetes
Pharmacologic Agents for Treatment of Type 2 Diabetes SCAN Drugs Medication Biguanides 1 1 er uncoated tabs 500 mg & 750 mg Sulfonylureas 1 1 500 850 mg QD - TID 500 2000 mg glimepiride 1 1 1 8 mg glipizide
More informationThe Many Faces of T2DM in Long-term Care Facilities
The Many Faces of T2DM in Long-term Care Facilities Question #1 Which of the following is a risk factor for increased hypoglycemia in older patients that may suggest the need to relax hyperglycemia treatment
More informationNew Drugs for Diabetes
NEW DRUGS FOR DIABETES Which Ones, For Which Patients? Disclosure Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine baron@medicine.ucsf.edu No relevant financial relationships
More informationDIABETES DEBATE - IS NEW BETTER?
DIABETES DEBATE - IS NEW BETTER? WHAT MEDICATION CLASS AFTER METFORMIN TO CONTROL BLOOD SUGAR Dr. Lydia Hatcher, MD, CCFP, FCFP, CHE, D-CAPM Associate Clinical Professor of Family Medicine, McMaster Chief
More informationDrugs used in Diabetes. Dr Andrew Smith
Drugs used in Diabetes Dr Andrew Smith Plan Introduction Insulin Sensitising Drugs: Metformin Glitazones Insulin Secretagogues: Sulphonylureas Meglitinides Others: Acarbose Incretins Amylin Analogues Damaglifozin
More informationType II Diabetes Improving Blood Sugar Control. Geneva Clark Briggs, Pharm.D., BCPS
Type II Diabetes Improving Blood Sugar Control Geneva Clark Briggs, Pharm.D., BCPS Overview Importance of glucose control State of control Review available therapies Helping patients achieve control The
More informationNew Therapies for Diabetes
Type 2 diabetes is increasingly prevalent New Therapies for Diabetes Lynn Mack, M.D. Associate Professor Diabetes, Endocrinology, & Metabolism The Nebraska Medical Center lmack@unmc.edu No Conflicts of
More informationHot Topics: The Future of Diabetes Management Cutting Edge Medication and Technology-Based Care
Hot Topics: The Future of Diabetes Management Cutting Edge Medication and Technology-Based Care Mary Jean Christian, MA, MBA, RD, CDE Diabetes Program Coordinator UC Irvine Health Hot Topics: Diabetes
More informationCURRENT ISSUES IN DIABETES MANAGEMENT
CURRENT ISSUES IN DIABETES MANAGEMENT Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest Screening for Diabetes 2011 BMI
More informationPractical Strategies for the Clinical Use of Incretin Mimetics CME/CE. CME/CE Released: 09/15/2009; Valid for credit through 09/15/2010
Practical Strategies for the Clinical Use of Incretin Mimetics CME/CE Robert R. Henry, MD Authors and Disclosures CME/CE Released: 09/15/2009; Valid for credit through 09/15/2010 Introduction Type 2 diabetes
More informationClinical Practice Guidelines
Clinical Practice Guidelines Diabetes Objective The purpose is to guide the appropriate diagnosis and management of Diabetes. This guideline is designed to assist the clinician by providing a framework
More informationDiabetes Risk Assessment and Treatment
Diabetes Risk Assessment and Treatment Todd T. Brown, MD, PhD Professor of Medicine and Epidemiology Division of Endocrinology, Diabetes, & Metabolism Johns Hopkins University Baltimore, Maryland, USA
More informationDisclosure. Learning Objectives. Case. Diabetes Update: Incretin Agents in Diabetes-When to Use Them? I have no disclosures to declare
Disclosure Diabetes Update: Incretin Agents in Diabetes-When to Use Them? I have no disclosures to declare Spring Therapeutics Update 2011 CSHP BC Branch Anar Dossa BScPharm Pharm D CDE April 20, 2011
More informationOBJECTIVES 4/7/2014. Diabetes Update Overview of the Diabetes Epidemic in the United States. ISHP Annual Spring Meeting
Diabetes Update 2014 ISHP Annual Spring Meeting Hayley Miller MD April 13, 2014 OBJECTIVES Review diabetes guidelines. Understand diabetes management targets. Discuss current therapeutic strategies. Overview
More informationJoslin Diabetes Center Advances in Diabetes and Thyroid Disease 2013 Noninsulin Treatment of Diabetes: What the PCP Needs to Know
Non Insulin Treatment of Type 2 Diabetes: What the PCP Needs to Know Martin J. Abrahamson, MD Senior Vice President for Medical Affairs Joslin Diabetes Center Associate Professor of Medicine Harvard Medical
More informationUpdate on Therapies for Type 2 Diabetes: Angela D. Mazza, DO July 31, 2015
Update on Therapies for Type 2 Diabetes: 2015 Angela D. Mazza, DO July 31, 2015 Objectives To present the newer available therapies for the management of T2D To discuss the advantages and disadvantages
More informationAgenda. Indications Different insulin preparations Insulin initiation Insulin intensification
Insulin Therapy F. Hosseinpanah Obesity Research Center Research Institute for Endocrine sciences Shahid Beheshti University of Medical Sciences November 11, 2017 Agenda Indications Different insulin preparations
More informationSodium-Glucose Co-Transporter 2 (SGLT-2) Inhibitors Drug Class Prior Authorization Protocol
Sodium-Glucose Co-Transporter 2 (SGLT-2) Inhibitors Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has
More informationMr Rab Burtun. Dr David Kim. 8:30-10:30 WS #2: Diabetes Basic 11:00-13:00 WS #9: Diabetes Basic (Repeated)
Dr David Kim Endocrinologist and General Physician Waitemata DHB and Apollo Specialist Clinic Albany Auckland Mr Rab Burtun Diabetes Nurse Specialist Waitemata DHB Waitakere Hospital Auckland 8:30-10:30
More informationThe Death of Sulfonylureas? A Review of New Diabetes Medications
The Death of Sulfonylureas? A Review of New Diabetes Medications Kelly Hoenig, Pharm.D., BCPS Cedar Rapids Family Medicine Residency 2/4/17 Objectives Review GLP-1 Agonists, DPP-IV Inhibitors and SGLT-2
More informationOlder Adults & Optimal Outcome. Individualizing Diabetes Management. Mary Moyer Janci BC-FNP BC-ADM CDE Teaching Associate Diabetes Care Center UWMC
Older Adults & Optimal Outcome Individualizing Diabetes Management Mary Moyer Janci BC-FNP BC-ADM CDE Teaching Associate Diabetes Care Center UWMC What is Diabetes? METABOLIC DISEASE Food breakdown (carbohydrates,
More informationGlyceamic control is indicated by 1. Fasting blood sugar less than 126 mg/dl 2. Random blood sugar 3. HbA1c less than 6.5 % Good glycaemic control
Glyceamic control is indicated by 1. Fasting blood sugar less than 126 mg/dl 2. Random blood sugar 3. HbA1c less than 6.5 % Good glycaemic control can prevent many of early type 1 DM(in DCCT trail ). UK
More informationDrug Class Monograph
Drug Class Monograph Class: Sodium-Glucose Co-Transporter 2 (SGLT-2) Inhibitors Drugs: Farxiga (dapagliflozin), Invokamet (canagliflozin/metformin), Invokana (canagliflozin), Jardiance (empagliflozin),
More informationType. Diabetes Drugs. A Review
Type Diabetes is a common diagnosis for home care patients. Diabetes drugs are now available that target the multiple defects of metabolism that characterize Type 2 diabetes. Understanding the wide variety
More informationAge-adjusted Percentage of U.S. Adults Who Were Obese or Who Had Diagnosed Diabetes
Age-adjusted Percentage of U.S. Adults Who Were Obese or Who Had Diagnosed Diabetes Obesity (BMI 30 kg/m 2 ) 1994 2000 2009 No Data 26.0% Diabetes 1994 2000 2009
More informationReviewing Diabetes Guidelines. Newsletter compiled by Danny Jaek, Pharm.D. Candidate
Reviewing Diabetes Guidelines Newsletter compiled by Danny Jaek, Pharm.D. Candidate AL AS KA N AT IV E DI AB ET ES TE A M Volume 6, Issue 1 Spring 2011 Dia bet es Dis pat ch There are nearly 24 million
More informationCURRENT ISSUES IN DIABETES MANAGEMENT
CURRENT ISSUES IN DIABETES MANAGEMENT Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest Diabetes Mellitus: U.S. Impact DIABETES
More informationIntensification of Diabetic Therapy. Case studies
Intensification of Diabetic Therapy Case studies Patient #1 1 st visit: 64 year old male, H/O prediabetes, lost weight 280 lbs. to 240 lbs. ER for dental abscess, glucose >300 A1C 11.4%, no diabetic medication,
More informationDiabetes: Inpatient Glucose control
Diabetes: Inpatient Glucose control Leanne Current, PharmD, BCPS This activity is funded through the Medicaid section 1115(a) Demonstration Texas Healthcare Transformation and Quality Improvement Program
More informationPhysiology of Normoglycemia
Case 1 45 year-old male patient seen at the clinic (Medicine). Workplace stress (financial analyst); occasionally goes jogging. Two-year duration of T2DM. No previous cardiovascular events. Coexisting
More informationManagement of Hyperglycemia in Type 2 Diabetes Celeste C. Thomas MD, MS
Management of Hyperglycemia in Type 2 Diabetes Celeste C. Thomas MD, MS Disclosures In compliance with the accrediting board policies, the American Diabetes Association requires the following disclosure
More informationObjectives. Kidney Complications With Diabetes. Case 10/21/2015
Objectives Kidney Complications With Diabetes Brian Boerner, MD Diabetes, Endocrinology, and Metabolism University of Nebraska Medical Center Review screening for, and management of, albuminuria Review
More informationThe ABCs (A1C, BP and Cholesterol) of Diabetes
The ABCs (A1C, BP and Cholesterol) of Diabetes Gregg Simonson, PhD Director, Professional Training and Consulting International Diabetes Center; Adjunct Assistant Professor, University of Minnesota Department
More informationFUNDING: MICIS mandated by Maine Legislature, funded by fees collected from pharmaceutical companies as a cost of doing business in the state.
GOAL: To improve clinical outcomes by delivering upto-date, evidence-based prescribing information, using data and guidelines developed by noncommercial sources FUNDING: MICIS mandated by Maine Legislature,
More informationDiabetes Mellitus. Intended Learning Objectives:
Intended Learning Objectives: Diabetes Mellitus 1. Compare and contrast the differences between the drug therapy recommendations of several of the latest and leading diabetes guidelines. 2. Assess the
More informationWhat s New in Type 2 Diabetes? 2018 Diabetes Updates
What s New in Type 2 Diabetes? 2018 Diabetes Updates Gretchen Ray, PharmD, PhC, BCACP, CDE Associate Professor, UNM College of Pharmacy January 28, 2018 gray@salud.unm.edu OBJECTIVES Describe the most
More informationProfessor Rudy Bilous James Cook University Hospital
Professor Rudy Bilous James Cook University Hospital Rate per 100 patient years Rate per 100 patient years 16 Risk of retinopathy progression 16 Risk of developing microalbuminuria 12 12 8 8 4 0 0 5 6
More informationHow to Use the ADA Type 2 Diabetes Treatment Algorithm. Eric L. Johnson, MD Jay Shubrook, Jr., DO, FACOFP
How to Use the ADA Type 2 Diabetes Treatment Algorithm Eric L. Johnson, MD Jay Shubrook, Jr., DO, FACOFP 8 ACOFP 55th Annual Convention & Scientific Seminars ACOFP FULL DISCLOSURE FOR CME ACTIVITIES Please
More information